



## **Biora Therapeutics Shares Data Presented at Digestive Disease Week 2022**

May 25, 2022

### **Patient Data Suggests Multiple Additional Inflammatory Pathways, Supporting Potential Need for Combination Therapy for Ulcerative Colitis**

#### **Patient Data Establishes Proof of Concept for Microbiome Sampling Capsule**

SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- [Biora Therapeutics, Inc.](https://www.bioratherapeutics.com) (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared two posters that were presented during the Digestive Disease Week® (DDW), May 21-24, 2022 in San Diego. DDW is the world's premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

During Tuesday's poster session, author Dr. Geert D'Haens shared the poster titled "Pharmacokinetic stratification of cytokine profiles during anti-TNF induction treatment in moderate-to-severe UC," which explores potential causes for the 30% of patients who are primary non-responders to anti-TNF therapies. The pro-inflammatory cytokine interleukin 6 (IL6) was observed at high levels in tissue, suggesting it may be a driver of inflammation alternative to TNF in ulcerative colitis (UC). This data suggests a need for combination therapy to target multiple inflammatory pathways in patients with UC. This data was also presented at the 17th Congress of the European Crohn's and Colitis Organisation.

"The multiple inflammatory pathways that contribute toward the pathophysiology of ulcerative colitis suggest the need for combination therapy to improve overall outcomes for patients with UC, but combination therapies must overcome the systemic toxicity limits of current approaches," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "Our targeted therapeutics platform is designed to achieve higher doses in tissue while significantly reducing toxicity due to systemic uptake. Reduced systemic uptake could open the door for combination therapy to simultaneously target multiple inflammatory pathways. We believe that this could improve therapeutic outcomes for the large number of UC patients who today are unable to achieve remission of symptoms."

On Tuesday, Biora Therapeutics also shared a poster titled "A novel method for collecting microbiome specimens: proof of concept in normal healthy volunteers" which presents patient data on Biora's Recoverable Sample System (RSS) capsule, an ingestible capsule designed for noninvasive collection of an intestinal fluid specimen while the capsule passes naturally through the gastrointestinal tract. The RSS capsule is designed to recognize anatomical features within the GI tract and sample intestinal fluid at a pre-programmed, targeted location, such as the proximal large intestine. This precision sampling may be used to provide more insight on specific drug targets in the intestine. The study suggests that samples from distinct locations in the GI tract can be different from fecal samples and may offer unique insights into microbiome research, which can be advantageous in the development of precision therapeutics. The company continues to incubate this technology in addition to its two primary therapeutic platforms.

Both posters can be viewed by visiting [bioratherapeutics.com/publications](https://www.bioratherapeutics.com/publications).

#### **About Biora Therapeutics**

Biora Therapeutics is the biotech company that is reimagining therapeutics. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients' lives. Biora envisions a world where patients have access to needle-free drug delivery and better therapeutic outcomes.

For more information, visit [bioratherapeutics.com](https://www.bioratherapeutics.com) or follow the company on [LinkedIn](https://www.linkedin.com/company/bioratherapeutics) or [Twitter](https://twitter.com/bioratherapeutics).

#### **Safe Harbor Statement or Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations of our research and development efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of precision medicine, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding future revenue generating opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, the ongoing COVID-19 pandemic, and those risks described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events

or otherwise, except as required by law.

**Investor Contact**

Chuck Padala  
Managing Director, LifeSci Advisors  
[IR@bioratherapeutics.com](mailto:IR@bioratherapeutics.com)  
(646) 627-8390

**Media Contact**

[media@bioratherapeutics.com](mailto:media@bioratherapeutics.com)